2025-8-1

In June 2025, InnovaRadi, in collaboration with West China Hospital of Sichuan University and Sichuan University, launched the first-in-Global   exploratory clinical trial of [²¹¹At]-MABG for the treatment of high-risk neuroblastoma . The trial aims to evaluate the safety, tolerability, and preliminary efficacy of [²¹¹At]-MABG in patients with relapsed or refractory neuroblastoma. The first patient dosing was successfully completed on July 18, 2025.   

Neuroblastoma (NB) is a highly malignant tumor originating from the sympathetic nervous system, overly expressing the norepinephrine transporter (NET). As the most common extracranial solid malignant tumor in children, NB accounts for 8%-10% of childhood malignancies but contributes to 15% of childhood cancer-related deaths. It exhibits diverse biological behaviors and complex etiologies; particularly for high-risk NB, tumor heterogeneity is more prominent, and early metastasis is common. Despite undergoing multiple treatment modalities (e.g., chemotherapy, radiotherapy, surgery, and immunotherapy), the overall survival rate of patients with high-risk NB remains low. Recurrence and drug resistance are major challenges, with the overall survival rate of relapsed or refractory cases still below 40%. Therefore, the development of more precise and effective targeted therapeutic drugs is imperative.   

Clinical Trial Update (June 2025)